Hodgkin Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Lymphoma (957)

Non-Hodgkin’s Lymphoma (832)

Lymphoma (957)

Non-Hodgkin’s Lymphoma (832)

›

TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials SOHO 2022 - 1 week (New C3) CD30-targeted CAR-T immunotherapy Sensitive : C3 SOHO 2022 - 1wk	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials SOHO 2022 - 1 week CD30-targeted CAR-T immunotherapy Sensitive : C3 SOHO 2022 - 1 week - (New C3)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval NCCN - 2 weeks (New A2) brentuximab vedotin Sensitive : A1 NCCN - 2wk	brentuximab vedotin Sensitive: A1 - Approval NCCN - 2 weeks brentuximab vedotin Sensitive : A1 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab Sensitive: A1 - Approval NCCN - 2 weeks (New A2) nivolumab Sensitive : A1 NCCN - 2wk	nivolumab Sensitive: A1 - Approval NCCN - 2 weeks nivolumab Sensitive : A1 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	rituximab/hyaluronidase Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) rituximab / hyaluronidase Sensitive : A2 NCCN - 2wk	rituximab/hyaluronidase Sensitive: A2 - Guideline NCCN - 2 weeks rituximab / hyaluronidase Sensitive : A2 NCCN - 2 weeks - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	vinblastine Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) vinblastine Sensitive : A2 NCCN - 2wk	vinblastine Sensitive: A2 - Guideline NCCN - 2 weeks vinblastine Sensitive : A2 NCCN - 2 weeks - (New A2)
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1	penpulimab Sensitive: A1 - Approval penpulimab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	AB122 Sensitive: A1 - Approval AB122 Sensitive : A1	AB122 Sensitive: A1 - Approval AB122 Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2	R-CHOP Sensitive: A2 - Guideline R-CHOP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2	R-CVP Sensitive: A2 - Guideline R-CVP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	ICE Sensitive: A2 - Guideline ICE Sensitive : A2	ICE Sensitive: A2 - Guideline ICE Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	ESHAP Sensitive: A2 - Guideline ESHAP Sensitive : A2	ESHAP Sensitive: A2 - Guideline ESHAP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	R-ESHAP Sensitive: A2 - Guideline R-ESHAP Sensitive : A2	R-ESHAP Sensitive: A2 - Guideline R-ESHAP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	MINE Sensitive: A2 - Guideline MINE Sensitive : A2	MINE Sensitive: A2 - Guideline MINE Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	BEACOPP Sensitive: A2 - Guideline BEACOPP Sensitive : A2	BEACOPP Sensitive: A2 - Guideline BEACOPP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	IGEV Sensitive: A2 - Guideline IGEV Sensitive : A2	IGEV Sensitive: A2 - Guideline IGEV Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	GVD Sensitive: A2 - Guideline GVD Sensitive : A2	GVD Sensitive: A2 - Guideline GVD Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	GDP Sensitive: A2 - Guideline GDP Sensitive : A2	GDP Sensitive: A2 - Guideline GDP Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	EPIC Sensitive: A2 - Guideline EPIC Sensitive : A2	EPIC Sensitive: A2 - Guideline EPIC Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	BEAM Sensitive: A2 - Guideline BEAM Sensitive : A2	BEAM Sensitive: A2 - Guideline BEAM Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	Bv-AVE-PC Sensitive: B - Late Trials Bv-AVE-PC Sensitive : B	Bv-AVE-PC Sensitive: B - Late Trials Bv-AVE-PC Sensitive : B
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2	AFM13 Sensitive: C2 – Inclusion Criteria AFM13 Sensitive : C2
CHD8 mutation	Hodgkin Lymphoma	CHD8 mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
CELF2 mutation	Hodgkin Lymphoma	CELF2 mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
ABCC2 underexpression	Hodgkin Lymphoma	ABCC2 underexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
PD-1 underexpression	Hodgkin Lymphoma	PD-1 underexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3

Hodgkin Lymphoma

Associations(55)

Associations
(55)